Oryzon Genomics S.A.
Oryzon Genomics S.A. (ORY.MC) Stock Overview
Explore Oryzon Genomics S.A.’s financial performance, market position, analyst ratings, and future outlook.
Key Financials
Key Financials
Market Cap
218.2M
P/E Ratio
-51.07
EPS (TTM)
$-0.06
ROE
-0.04%
ORY.MC Stock Analysis & Investment Overview
Our comprehensive AI-powered analysis of Oryzon Genomics S.A. (ORY.MC) provides investors with deep insights into the stock's performance, growth potential, and market positioning. With a Meyka AI Score of F, this stock demonstrates moderate investment characteristics based on our advanced machine learning models.
The current technical analysis reveals key indicators including an RSI of 54.64, suggesting the stock is in a neutral condition. Our forecasting models predict significant price movements, with a 12-month target of $1.70.
Key financial metrics showcase the company's fundamental strength, including a P/E ratio of -51.07 and a market capitalization of 218.2M. These metrics, combined with our AI analysis, provide a comprehensive view for both institutional and retail investors.
Technical Indicators
Company Profile
Oryzon Genomics S.A., a clinical stage biopharmaceutical company, engages in the discovery and development of epigenetics-based therapeutics for patients with cancer and CNS disorders. Its clinical phase compounds include iadademstat (ORY-1001), a selective LSD1 inhibitor that is in Phase II trials for oncology; and vafidemstat (ORY-2001), a CNS-optimized LSD1 inhibitor, which is in Phase II trials for the treatment of CNS and psychiatric diseases. Its product candidates also comprise ORY-3001, an LSD1 inhibitor that is in preclinical development for the treatment of non-oncological diseases. The company was founded in 2000 and is based in Cornellà de Llobregat, Spain.
Carlos Manuel Buesa Arjol
47
Sant Ferran 74, Cornellà de Llobregat
2015